Abstracts

Platform-Disease Modifying Therapies

Design of the Phase II, Double-Blind, Placebo-Controlled Dose-Expansion Portion of a Two-Part, Phase I/II, Multicenter Trial in Progressive Multiple Sclerosis

Background: Infection with Epstein-Barr virus (EBV) is a necessary risk factor for the development of multiple sclerosis (MS) Abrahamyan S...

Read More

Platform-Disease Management

How the COVID-19 Pandemic Has Changed Multiple Sclerosis Clinical Practice: Results of a Nationwide Provider Survey

Background: The COVID-19 crisis has created unanticipated changes in health care delivery for people living with multiple sclerosis (MS)....

Read More

Platform-Psychosocial

No One Really Plans to Have MS: Transition Readiness and Quality of Life in Pediatric Multiple Sclerosis

Background: Pediatric MS, defined as onset before the age of 18, is estimated to occur in over 8,000 children in the United States with...

Read More

Platform-Disease Management

Associations of Structural Visual Metrics with Moderate to Vigorous Physical Activity in Youth with Pediatric Onset Neuroinflammatory Disorders

Background: Previous research has shown that higher levels of moderate to vigorous physical activity (MVPA) associate with lower brain...

Read More

Platform-Rehabilitation

The Effect of Telerehabilitation on the Quality of Life and Fatigue of Patients with Multiple Sclerosis

Background: , Multiple Sclerosis is a chronic neurological disease, characterized by demyelination of neurons in the Central Nervous System...

Read More

Platform-Disease Management

Development and Usability Testing of a Patient-Based Digital Tool to Detect Early Signs of Changes in Multiple Sclerosis Symptoms and Progression: Your MS Questionnaire

Background: The validated physician-completed MSProDiscussTM tool facilitates physician-patient interaction in evaluating early signs of...

Read More

Platform-Disease Management

Characterizing Socioeconomic, Lifestyle, and Comorbidity Mediators of Racial Disparities in Ambulatory Impairments in Multiple Sclerosis.

Background: Multiple sclerosis (MS) is more prevalent in White Americans (WAs), yet incidence is now highest in Black Americans (BAs), who...

Read More

Platform-Disease Modifying Therapies

Efficacy and Safety of Ublituximab Versus Teriflunomide in Relapsing Multiple Sclerosis: Results of the Phase 3 Ultimate I and II Trials

Background: Ublituximab, a novel monoclonal antibody, targets a unique epitope on the CD20 antigen and is glycoengineered for enhanced...

Read More

Platform-Rehabilitation

Beyond the Physical Symptoms of Spasticity for Persons with MS Spasticity: Results from SEEN-MSS, a Large-Scale, Self-Reported Survey

Background: Spasticity, a complex and multi-dimensional symptom of multiple sclerosis (MS), occurs in up to 80% of those with MS. It is...

Read More

Platform-Psychosocial

Living with Multiple Sclerosis: Perceptions, Conflicts and Coping

Background: A physical illness causes pain and suffering to not just the person who is diagnosed but also impacts the lives of family...

Read More